Recent Findings Confirm LIM Domain Kinases as Emerging Target Candidates for Cancer Therapy
Author(s): F. Manetti. Dipartimento Farmaco Chimico Tecnologico, Universita degli Studi di Siena, via Alcide de Gasperi 2, I-53100 Siena, Italy.
Journal Name: Current Cancer Drug Targets
Volume 12 , Issue 5 , 2012
DOI : 10.2174/156800912800673266
The two members of the LIM domain kinase family (LIMK1 and LIMK2) represent crucial keys in the signaling pathways that modulate the structure and activity of actin cytoskeleton. They maintain the optimal balance between phosphorylated and unphosphorylated cofilin that in turn acts by severing filamentous actin into globular actin and ensures actin turnover and cytoskeleton regulation. Many macromolecular partners able to regulate LIMK activity (positive and negative regulators) do exist. Proteins that enhance or reduce the nucleocytoplasmic shuttling of LIMK by direct or indirect interaction are also known. Among many LIMK activators, members of the Rho family of small GTPases (i.e., Rho, Rac, and Cdc42) and their downstream effectors (i.e., ROCK, PAK, and MK2) are involved in the progression of various human cancers toward invasive and metastatic stages. As LIMK are centrally positioned in the pathways leading to cytoskeleton dynamics and regulation, they could be considered as valuable targets for actin regulation. Fine modulation of LIMK activity could be a major challenge to inhibit tumor cell invasion mediated by one or a combination of the upstream signaling factors. As LIMK play a critical role in tumor cell invasion, they may be candidate targets for developing novel therapeutic agents toward tumor invasion and metastasis.
Keywords: Actin cytoskeletal dynamics, actin-depolymerizing factor, cofilin, cancer cells, LIM domain kinases, metastasis, small molecule LIMK inhibitors
Current Cancer Drug Targets
Title:Recent Findings Confirm LIM Domain Kinases as Emerging Target Candidates for Cancer Therapy
VOLUME: 12	ISSUE: 5
Author(s):F. Manetti
Affiliation:Dipartimento Farmaco Chimico Tecnologico, Universita degli Studi di Siena, via Alcide de Gasperi 2, I-53100 Siena, Italy.
Keywords:Actin cytoskeletal dynamics, actin-depolymerizing factor, cofilin, cancer cells, LIM domain kinases, metastasis, small molecule LIMK inhibitors
Abstract:The two members of the LIM domain kinase family (LIMK1 and LIMK2) represent crucial keys in the signaling pathways that modulate the structure and activity of actin cytoskeleton. They maintain the optimal balance between phosphorylated and unphosphorylated cofilin that in turn acts by severing filamentous actin into globular actin and ensures actin turnover and cytoskeleton regulation. Many macromolecular partners able to regulate LIMK activity (positive and negative regulators) do exist. Proteins that enhance or reduce the nucleocytoplasmic shuttling of LIMK by direct or indirect interaction are also known. Among many LIMK activators, members of the Rho family of small GTPases (i.e., Rho, Rac, and Cdc42) and their downstream effectors (i.e., ROCK, PAK, and MK2) are involved in the progression of various human cancers toward invasive and metastatic stages. As LIMK are centrally positioned in the pathways leading to cytoskeleton dynamics and regulation, they could be considered as valuable targets for actin regulation. Fine modulation of LIMK activity could be a major challenge to inhibit tumor cell invasion mediated by one or a combination of the upstream signaling factors. As LIMK play a critical role in tumor cell invasion, they may be candidate targets for developing novel therapeutic agents toward tumor invasion and metastasis.
F. Manetti, "Recent Findings Confirm LIM Domain Kinases as Emerging Target Candidates for Cancer Therapy", Current Cancer Drug Targets (2012) 12: 543. https://doi.org/10.2174/156800912800673266
https://doi.org/10.2174/156800912800673266 Print ISSN
Page: [543 - 560]
DOI: 10.2174/156800912800673266
PDF: 9
Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC)
Androgen Pathway Related Gene Variants and Prostate Cancer Association in Auckland Men
Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics)
Exploring Cancer Therapeutics with Natural Products from African Medicinal Plants, Part II: Alkaloids, Terpenoids and Flavonoids
Editorial (Thematic Issue: New Drug Targets for Treatment of Recurrent/Metastatic Prostate Cancer)
Current Drug Targets
Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Synthesis, Molecular Modelling and Antibacterial Activity Against Helicobacter pylori of Novel Diflunisal Derivatives as Urease Enzyme Inhibitors
Letters in Drug Design & Discovery
Carcinoembryonic Antigen (CEA)-Based Cancer Vaccines: Recent Patents and Antitumor Effects from Experimental Models to Clinical Trials
Recent Patents on Anti-Cancer Drug Discovery
III. Angiogenesis: Complexity of Tumor Vasculature and Microenvironment
Novel Series of Coumarinyl Substituted-thiazolidin-2,4-dione Analogs as Anticancer Agents: Design, Synthesis, Spectral Studies and Cytotoxicity Evaluation
Meet Our Editorial:
Editorial [ The Role of Epidermal Growth Factor Receptor (EGFR) Targeting Drugs in the Treatment of Cancer Guest Editor: Fortunato Ciardiello ]
Current Cancer Therapy Reviews
CCK Receptors and Cancer
Current Topics in Medicinal Chemistry
Application of GA-MLR for QSAR Modeling of the Arylthioindole Class of Tubulin Polymerization Inhibitors as Anticancer Agents
Metastatic Gastro-intestinal Neuroendocrine Tumors: A Case Report of Real Life Management Challenges and Success
Combination of Valproic Acid and ATRA Restores RARβ2 Expression and Induces Differentiation in Cervical Cancer through the PI3K/Akt Pathway
Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab
Insulin-like Growth Factor I Receptor: A Novel Target for Hepatocellular Carcinoma Gene Therapy
Mini-Reviews in Medicinal Chemistry
Comparison of Radiohaloanalogues of Meta-Iodobenzylguanidine (MIBG) for a Combined Gene- and Targeted Radiotherapy Approach to Bladder Carcinoma
Pharmacokinetics of Gefitinib: Roles of Drug Metabolizing Enzymes and Transporters
Current Drug Delivery